betting 365 Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, betting 365 Kabi focuses on autoimmune diseases and oncology. Within transfusion technology, betting 365 Kabi offers products used in the collection and processing of blood and cell components, as well as in transfusion medicine and cell therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
betting 365 Kabi employs over 40,000 people worldwide. In 2019 the company reported sales of more than €6.9 billion. betting 365 Kabi AG is a wholly owned subsidiary of the betting 365 SE & Co. KGaA health care group.